Abstract
Introduction

Recent years have seen enormous advances in the field of stem cell biology and applications thereof. The two unique properties of stem cells, those of developmental plasticity and extended proliferative potential in vitro, make them ideal candidates for use in cell replacement therapies. However, before such practical applications can be pursued, it is essential that we elucidate the fundamental mechanisms that govern their stable propagation and differentiation.
Despite the extensive use of bone marrow transplants for blood-related disorders, the concept of 'stem cell therapies' has only effectively been coined since the isolation of human embryonic stem cells (hESCs) [1] . Indeed, the link between stem cell research and the notion of 'regenerative medicine ' [2] , inflammatory bowel disease [3, 4] , myocardial infarction [5, 6] , graft-versus-host disease [7, 8] and a variety of autoimmune disorders [9] [10] [11] [12] . Furthermore, the potential of ASCs to regenerate damaged tissue at so called 'immunologically privileged' sites is also being explored. Such studies include the restoration of neural function in neuroimmune/neurodegenerative conditions and in traumatic injury of the central nervous system [10, 13] , as well as treatment of ocular lesions, autoimmune-related retinopathy and optic neuropathy [14] .
The
source of cells to be used for any given therapy is of major concern and must be addressed on a case-by-case basis. Ideally the cells should be easily accessible, pluripotent, genetically stable, exhibit high growth potential and not be subject to immunorejection. Differentiated cells can be autogenic but do not meet the pluripotency criterion and are not easily expanded. For these reasons the primary focus of cell transplantation therapies has been on embryonic stem cells (ESCs) and ASCs. The regenerative potential of ESCs has now been successfully tested in several basic and preclinical studies. For instance, ESCderived dopaminergic neurons were able to restore neuronal function in rats treated with 6-hydroxydopamine, a model for
Parkinson's disease [15] [16] [17] [18] [19] . Furthermore, ESCs differentiated along an oligodendrocyte lineage were able to induce central nervous system remyelination in rodents [16, 20] . Other examples include the regeneration of musculoskeletal tissue in mdx dystrophic mice [21, 22] , infarcted myocardial tissue in mice [23, 24] , rats [25] and pigs [26] and dysfunction rescue of pancreatic islet cells in streptozotocin-treated mice [27] [28] [29] [30] [31] . However, the widespread clinical use of ESCs cannot be achieved without first addressing inherent problems such as teratoma formation [32, 33] and graft rejection [11] . A further concern which applies to both ASCs [11, [34] [35] [36] [32, 33, 56, 57] . A number of strategies have been proposed to address this problem, including improved screening [58] and the use of suicide genes [59] [60] [61] [62] [63] . A further concern is the risk of genomic instabilities which may accumulate as a result of long-term cell [1, 54, 64, 65] , recent evidence strongly suggests that the adaptation of these cells to prolonged culture favours the development of chromosomal and sub-chromosomal alterations [66] . As the molecular mechanisms that control the in vitro proliferative adaptation and malignant transformation are fundamentally similar [67] , the overall safety of hESC-based therapies must be thoroughly examined [68, 69] [73, 75] . Oct3/4 gene expression has occasionally been reported in mesenchymal stem cells [76, 77] , although the role of this factor in maintaining self-renewal/pluripotency in ASCs has not yet been defined [78] . Mesenchymal stem cells are obvious candidates for regenerative therapies involving the reconstruction of connective tissues and wound healing [79, 80] . Particularly promising results have been reported for Crohn's disease [2] and myocardial infarction [81] . However, the most intriguing characteristic of mesenchymal stem cells is their purported ability to act as immunomodulators [82] [83] [84] [85] and pro-angiogenic agents [79, 86] , the latter potentially mediated through the secretion of a variety of trophic signals that favour engraftment and/or endogenous regeneration [87] . 
Limitations of stem cells
Based on some of the issues already discussed, it has been proposed that stem cell research be limited to ASCs. However, the counter argument is that ESCs have the highest potential to become a clinical reality [102] . The most important differences between embryonic and ASCs are highlighted in [171, 172] Patient specific cell-based therapies to reach a low immunogenicity: SCNT strategies [108, 170] Requirement for novel protocol with defined medium, and replacement of animal proteins by human ones [173] Risk of tumour formation for transplant therapy [1, 33] Requirement for pure differentiated cell population Epigenetic instability [174] and chromosomal abnormalities [66] Slow progression towards clinical applications [70] Ethical concerns [124, 170, 175] [105, 106] . [112] [113] [114] [115] or fusion with ESCs [116] . However, none of these provided a definitive solution to the problem. A different approach was used to achieve success. [117] and in shortly thereafter in human beings [118] . Similar results were independently reported by another team using a slightly different set of transcription factors (Oct3/4, Sox2, Nanog and LIN28) [119] . [120] . [122, 123] [124] .
Alternatives to overcome the limitations of stem cells
It is now generally believed that hESCs might represent an unlimited source from which to derive tissues for regenerative medicine [1, 2]. Coupled to somatic cell nuclear transfer (SCNT) [48], hESC technologies also opened the door to the possibility of generating tissues genetically identical to those of the donor. The principle of this application, also termed 'therapeutic cloning', has already been proven in mice [49] and non-human primates [51]. The generation of hESCs from SCNT-derived embryos, however, has remained elusive. Reports to that effect by Hwang et al. [107-109] turned out to be fraudulent, and had to be retracted [110]. To date, no hESCs have been derived by SCNT, despite progress at obtaining human blastocysts [111]. Technical, logistic and ethical concerns (not to be discussed here) led to a quest for methods to reprogram somatic cells without the use of nuclear transfer. Of particular note were strategies that made use of cellular extracts
By delivering constitutively active copies of critical regulators of hESC homeostasis (Oct3/4, Sox2, c-Myc and Klf4), Takahashi and coworkers were able to reprogram adult fibroblasts into hES-like cells (induced pluripotent cells or iPS), first in mice
Not surprisingly, these studies were hailed as a major biological breakthrough. A method that was both conceptually and technically simple had been sufficient to reprogram differentiated cells from adult donors without the use of human embryos. The potential therapeutic implications were subsequently realized by Hanna and coworkers, who treated sickle cell anaemia in mice by autologous transplantation of iPS-derived haematopoietic progenitors
A caveat of these procedures, however, was that the gene combinations required for reprogramming were delivered using retroviral vectors; thus rendering the resulting iPS cells unusable for clinical purposes because of the risks of virus insertional mutagenesis and the potential subsequent reactivation of the reprogramming genes [121]. The recent report on the generation of iPS cells in a virus-free system addresses a critical safety concern for their potential use in regenerative medicine
Histocompatibility and immune rejection
In vivo engraftment and function of human stem cells is compromised by potential immunological barriers [125] . One of these barriers is the expression of HLAs on stem cells [126] . [127, 128] . Such [129] . hESCs and their differentiated progeny are, therefore, similar to any other nucleated cell of the human body with regard to their class I HLA expression, and can be recognized as foreign and targeted by CTL. In addition to MHC molecules, hESCs also express minor histocompatibility complex (mHC) antigens [125] . Although these are not as immunogenic as MHC antigens, they are sufficient to drive the immune system to reject the graft [130] .
Major histocompatibility complex (MHC) class I and II HLA antigens are master triggers of robust immunological rejection of grafts because they present antigens to T lymphocytes. Class I HLA molecules are crucial in presenting tumor antigens and viral antigens on the surface of infected cells to cytotoxic T lymphocytes (CTL). Specific CTLs can efficiently lyse a target cell upon recognition of MHC class I-presented antigen on the cell surface. Although undifferentiated hESCs do not express class II HLA molecules, they do exhibit some expression of the class I type. However, expression of class I HLA antigens increases with differentiation
an increase in expression is even more pronounced under infectious and inflammatory conditions where interferon (IFN)-␥ is abundant
Graft rejection can also be mediated through a mismatch in the ABO blood group system (ABO) antigens between the donor and the recipient [131] because of their high immunogenicity. To date, the ABO antigen expression status of hESCs and their differentiated derivatives is still unknown. Nevertheless, and as mentioned above, the generation of 'universal donor' pluripotent cells [132] , patientspecific stem cells and ABO compatible hESCs would also solve the problem [133] . [126] [127] [128] [129] , resulting in strong immune responses that can lead to graft rejection. Furthermore, gene expression profiling [129] [135, 136] and therefore can be used in monotherapy or combination immunotherapy of cell transplant rejection [122, 137, 138] . Therefore, strategies to assess the ability of ESCs to induce immune tolerance through NKT cells obtained from ESCs are highly sought after [138] . It is clear that not all conditions that would provide immune privilege to hESCs are met ( Table 1) , and that using hESCs in transplantation medicine needs additional interventions to establish immune tolerance to the graft.
Are ESCs immunogenic or immunoprivileged?
Immunogenicity and immune privilege at a given graft site are mutually exclusive, and their onset is dictated by a variety of factors on both donor's and recipient's sides. On one hand (as described earlier), HLA class I antigen expression is very low on hESCs but can rise to those levels found on adult cells if differentiated or exposed to IFN-␥
Overcoming the need for immune manipulation to avoid rejection
There are a few instances where stem cells could be used successfully to regenerate tissues without the need to silence the immune system. In 2005, Miki and coworkers succeeded in isolating human amnion epithelial cells with ESC-like properties [139, 140] .
This research suggests that the amnion, derived from term placentas after live birth, may be a useful and non-controversial source of stem cells for use in transplantation. Because these cells are a genetic match to the developing foetus, tissues derived from them in vitro will escape immune rejection if used to treat defects in that newborn. Cryopreservation of cells is also an option to provide a personalized tissue bank for use by the donor later in life.
With our current knowledge (as discussed earlier), it is possible to obtain ASCs from various tissues (Table 1) [143] .
Manipulating immune tolerance for stem cell-based therapies
The mechanisms leading to the removal of immune responsiveness, or tolerance, to a given antigen takes place in the thymus (central tolerance) or in the periphery (peripheral tolerance). T cells specific for 'self'-antigens are either deleted in the thymus or driven into a state of anergy in the periphery as a result of insufficient costimulation and regulatory T-cell induction. In the periphery, T cells can be driven into tolerance by the presence of tolerogenic dendritic cells (DC) or Treg. Tolerogenic DCs do not possess the full machinery required to stimulate T cells, rather, they induce anergy. Tolerogenic DCs have been
shown to prolong allograft survival [144] . Given their remarkable functional plasticity, DCs are easily rendered tolerogenic by culturing them with mesenchymal stem cells [145] . Treg, by virtue of their strong immunosuppressive potential on T cells, are crucial for establishing immune tolerance to self-antigens and preventing autoimmunity [146] . Joffre [151] . Enhanced production of lymphoid progenitor cells following transplantation was also achieved by administration of thymic growth factors such as IL-7 [152] and FLT3 ligand [153] . Rejuvenation of the thymus through blockade of sex steroids has been demonstrated in patients with prostate cancer [154] and in castrated mice [155] 
